Stay Updated with the Latest Abivax S.A. ABVX News in Real Time
Find ABVX news now at Meyka AI. Stay informed with the latest Abivax S.A. stocks updates, including price news, market analysis, and expert insights.
Abivax Shares Jump 3.91% After $920 Million Stock Offering Grows Beyond Expectations
Abivax shares climbed 3.91% on Nasdaq on July 2, 2026, after the French biotech confirmed its $920 million American Depositary Share offering. Underwriters exercised their full option, pushing gross proceeds well past the original $600 million target. The ADS offering priced at $125.00 apiece on July 1. Abivax (Nasdaq: ABVX, Euronext Paris: ABVX) said the…
Abivax Shares Soar 27% After Ulcerative Colitis Drug Shows Strong Results in Hard-to-Treat Patients
Abivax shares surged sharply after new clinical trial results for its ulcerative colitis treatment, obefazimod, showed strong performance in patients who previously failed standard therapies. The stock reaction reflects renewed investor confidence in the biotech pipeline and growing hopes for a breakthrough therapy in a difficult disease area. The move also comes at a time…
GSK Plc Announces $10.6B Nuvalent Acquisition to Boost Lung Cancer Pipeline; Stock Falls 3.24%
GSK Plc moved decisively on June 9, 2026. The British drugmaker agreed to acquire US-listed cancer drug developer Nuvalent for $10.6 billion in an all-cash deal, valuing Nuvalent at approximately $124 per share, a 40% premium to its last closing price. Net of cash acquired, GSK’s actual upfront investment totals $9.4 billion. GSK Plc stock…
Abivax Shares Plunge 32% Despite Positive Colitis Trial Results Amid Safety Concerns
French biotech company Abivax delivered some of the strongest ulcerative colitis trial results seen in recent years. Yet, Abivax Shares (ABVX) plunged more than 32% on June 2, 2026, as investors focused on safety concerns rather than efficacy data. The selloff came after the company released positive Phase 3 maintenance trial results for its lead…
Abivax Stock (EPA: ABVX) at 77.55 EUR, down 30.64% as Safety Signals Cloud Colitis Trial Results
Abivax Stock came under heavy pressure on June 2, 2026, after investors focused on safety concerns linked to its ulcerative colitis drug candidate, obefazimod. The stock fell 30.64% to 77.55 EUR even though the company reported stronger-than-expected Phase 3 trial results. The sharp selloff shows that safety signals can outweigh positive efficacy data in biotechnology…
ABIVAX SA Climbs 2.1% as Earnings Announcement Nears on May 25
ABVX.PA stock rises 2.1% to €105.1 ahead of May 25 earnings. Biotech firm faces profitability challenges with negative EPS of -4.83.
ABIVAX SA Stock Climbs 1.57% as Earnings Loom on May 25
ABVX.PA stock rises 1.57% to €97.10 ahead of May 25 earnings announcement. Biotech firm develops ABX464 for inflammatory and infectious diseases.
ABVX.PA ABIVAX SA (EURONEXT) -10.97% after hours 24 Mar 2026: catalysts ahead
ABVX.PA stock fell 10.97% after hours to EUR 97.40; analysis, Meyka AI grade and forecasts for investors.
Pre-market top loser: IPH.PA Innate Pharma €1.15 on 21 Mar 2026: earnings risk ahead
IPH.PA stock falls to €1.15 pre-market on 21 Mar 2026; analysis, grade, and Meyka AI forecast for near-term downside and catalysts